Cargando…
Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates
INTRODUCTION: The pharmacokinetics of vancomycin are highly variable among neonates, which makes dosing challenging in this population. However, adequate drug exposure is critical, especially when treating methicillin-resistant Staphylococcus aureus (MRSA) infections. Utilization of population pharm...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471056/ https://www.ncbi.nlm.nih.gov/pubmed/25998107 http://dx.doi.org/10.1007/s40121-015-0067-9 |
_version_ | 1782376838006308864 |
---|---|
author | Stockmann, Chris Hersh, Adam L. Roberts, Jessica K. Bhongsatiern, Jiraganya Korgenski, Ernest K. Spigarelli, Michael G. Sherwin, Catherine M. T. Frymoyer, Adam |
author_facet | Stockmann, Chris Hersh, Adam L. Roberts, Jessica K. Bhongsatiern, Jiraganya Korgenski, Ernest K. Spigarelli, Michael G. Sherwin, Catherine M. T. Frymoyer, Adam |
author_sort | Stockmann, Chris |
collection | PubMed |
description | INTRODUCTION: The pharmacokinetics of vancomycin are highly variable among neonates, which makes dosing challenging in this population. However, adequate drug exposure is critical, especially when treating methicillin-resistant Staphylococcus aureus (MRSA) infections. Utilization of population pharmacokinetic models and Bayesian methods offers the potential for developing individualized therapeutic approaches. To meet this need, a neonatal vancomycin population pharmacokinetic model was recently published. The current study sought to externally evaluate the predictive performance and generalizability of this model. METHODS: A retrospective chart review of neonates who received vancomycin and had ≥1 peak and ≥1 trough concentrations at five Intermountain Healthcare neonatal intensive care units from 2006 to 2013 was performed and served as the external validation cohort. The published population pharmacokinetic model was implemented in NONMEM 7.2 with the structural and variance parameter values set equal to the estimates reported previously. The model was then used to predict the first peak and trough concentration for each neonate in the validation cohort and the model prediction error and absolute prediction error were calculated. Normalized prediction distribution errors (NPDE) were also evaluated. RESULTS: A total of 243 neonates were studied with a median postmenstrual age of 33 (range: 23–54) weeks and a median weight of 1.6 (range: 0.4–6.8) kg. The model predicted the observed vancomycin concentrations with reasonable precision. For all vancomycin concentrations, the median prediction error was −0.8 (95% CI: −1.4 to −0.4) mg/L and the median absolute prediction error was 3.0 (95% CI: 2.7–3.5) mg/L. No trends in NPDE across weight, postmenstrual age, serum creatinine, or time after dose were observed. CONCLUSION: An evaluation of a recently published neonatal vancomycin population pharmacokinetic model in a large external dataset supported the predictive performance and generalizability of the model. This model may be useful in evaluating neonatal vancomycin dosing regimens and estimating the extent of drug exposure. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40121-015-0067-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4471056 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-44710562015-06-18 Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates Stockmann, Chris Hersh, Adam L. Roberts, Jessica K. Bhongsatiern, Jiraganya Korgenski, Ernest K. Spigarelli, Michael G. Sherwin, Catherine M. T. Frymoyer, Adam Infect Dis Ther Original Research INTRODUCTION: The pharmacokinetics of vancomycin are highly variable among neonates, which makes dosing challenging in this population. However, adequate drug exposure is critical, especially when treating methicillin-resistant Staphylococcus aureus (MRSA) infections. Utilization of population pharmacokinetic models and Bayesian methods offers the potential for developing individualized therapeutic approaches. To meet this need, a neonatal vancomycin population pharmacokinetic model was recently published. The current study sought to externally evaluate the predictive performance and generalizability of this model. METHODS: A retrospective chart review of neonates who received vancomycin and had ≥1 peak and ≥1 trough concentrations at five Intermountain Healthcare neonatal intensive care units from 2006 to 2013 was performed and served as the external validation cohort. The published population pharmacokinetic model was implemented in NONMEM 7.2 with the structural and variance parameter values set equal to the estimates reported previously. The model was then used to predict the first peak and trough concentration for each neonate in the validation cohort and the model prediction error and absolute prediction error were calculated. Normalized prediction distribution errors (NPDE) were also evaluated. RESULTS: A total of 243 neonates were studied with a median postmenstrual age of 33 (range: 23–54) weeks and a median weight of 1.6 (range: 0.4–6.8) kg. The model predicted the observed vancomycin concentrations with reasonable precision. For all vancomycin concentrations, the median prediction error was −0.8 (95% CI: −1.4 to −0.4) mg/L and the median absolute prediction error was 3.0 (95% CI: 2.7–3.5) mg/L. No trends in NPDE across weight, postmenstrual age, serum creatinine, or time after dose were observed. CONCLUSION: An evaluation of a recently published neonatal vancomycin population pharmacokinetic model in a large external dataset supported the predictive performance and generalizability of the model. This model may be useful in evaluating neonatal vancomycin dosing regimens and estimating the extent of drug exposure. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40121-015-0067-9) contains supplementary material, which is available to authorized users. Springer Healthcare 2015-05-22 2015-06 /pmc/articles/PMC4471056/ /pubmed/25998107 http://dx.doi.org/10.1007/s40121-015-0067-9 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Research Stockmann, Chris Hersh, Adam L. Roberts, Jessica K. Bhongsatiern, Jiraganya Korgenski, Ernest K. Spigarelli, Michael G. Sherwin, Catherine M. T. Frymoyer, Adam Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates |
title | Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates |
title_full | Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates |
title_fullStr | Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates |
title_full_unstemmed | Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates |
title_short | Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates |
title_sort | predictive performance of a vancomycin population pharmacokinetic model in neonates |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471056/ https://www.ncbi.nlm.nih.gov/pubmed/25998107 http://dx.doi.org/10.1007/s40121-015-0067-9 |
work_keys_str_mv | AT stockmannchris predictiveperformanceofavancomycinpopulationpharmacokineticmodelinneonates AT hershadaml predictiveperformanceofavancomycinpopulationpharmacokineticmodelinneonates AT robertsjessicak predictiveperformanceofavancomycinpopulationpharmacokineticmodelinneonates AT bhongsatiernjiraganya predictiveperformanceofavancomycinpopulationpharmacokineticmodelinneonates AT korgenskiernestk predictiveperformanceofavancomycinpopulationpharmacokineticmodelinneonates AT spigarellimichaelg predictiveperformanceofavancomycinpopulationpharmacokineticmodelinneonates AT sherwincatherinemt predictiveperformanceofavancomycinpopulationpharmacokineticmodelinneonates AT frymoyeradam predictiveperformanceofavancomycinpopulationpharmacokineticmodelinneonates |